Look at the fail to deliver data and it looks like there are 500,000 shares undelivered.
This will now be a news release stock. There are no sellers down here and contrary to some I do not think they company is selling.
I think procedures have already begun as the surgeons who we use as consultants like Sikora in Boston have to be doing some as it was a large clinical site.
You are just such a zealot you do not want to hear an opposing opinion. He sold stock at 11.71 and bought option stock at 2.11...The guy makes 700,000 a year..And he needs money? They stop mm-111 and its no problem. Their CSO leaves...MM 398 is dragging and what about all your #$%$ last year that 211 was going to be partnered. All I see from the company is presentations. While they have an extensive portfolio they have one deal and nothing from Network Biology. Ever think Sanofi gave it back because it didn't work? Its biotech and highly risky. Porter has 650,000 shares that he paid almost nothing for and he buys 5,000 shares and its a big deal. The CFO continues to sell.
I think MACK could be a good company, but there is a lot of risk here now and Bob Mulroy is not a good leader IMO. I will stop posting until the do a deal or the company tees up JPM for a deal.
Oh, I have never been short the stock and I sold my last position at $9.00...
Neither am I. We interrupt signals others send signals, but I think some are using our technology and they will be hard pressed to get around our patents. A lot of the stuff was outside my range of knowledge, but them seemed to be very inclusive patents. Least of my worries.
Vaccine trials are not expensive..Who told you that. Getting a drug to market is expensive. Vaccines are needles in arms and not long term daily doses of a drug or placebo.
Good thoughts, but the FDA will also consider me too type of devices. They are very concerned with what I believe in patent parlance is " prior art." I read ETRM's patents and discussed this with the company. They said they pay very close attention to anything that even hints of infringement. Last year when the NY Times Magazine had that article on Hacking The Human Body I thought the others in the field were infringing. I still think that is the case but there has been no attempt to bring anything to market or before the FDA.
ETRM I believe is already working on the next generation which will be half the size of the existing issue. That is a matter of common sense as a smaller item will be in front of the FDA next year.
Hey moron read the SEC filing...Mulroy sold 114,000 shares at 11.70 and excercised 273,000 options at $1.71....He didn't buy anything..do the math genius
Fidelity..another 20,000 is an odd lot...N.B. Novavax has a ton of cash and is going to sell $175MM in stock..
Here they come.
...Drying up. Shorts can't find stock that is deliverable. The next news will be pretty good. They continue to do what they said they would. May 15th corporate update will be fascinating. There is a lot more going on than meets the eye. Be patient
Get ready pal. Bob is going to hit you with 15 million shares...You don't need luck with MACK.
The biotechs are fine if they are making money.
Nevada wants to pass a law regarding obesity. The Ultimate Fat Cat Law.
If you can't open it Google Obesity.
Where do you get this lunatic notion from? They do a reverse spilt and have no shares in float??
Get a life..You do not know what you are talking about. Another moron on IGNORE
Correct..I said in another post it is the same 100,000 shares a bunch of wise gys are tossing around trying to get you to sell. There is nothing going on at the company except trying to get VBLOC rolling and it is.
Corruption?? If there is corruption it is in the market that is trading this stock. If you have enough capital you can pretty much do what you want in a stock that trades at $1.00. Keep an eye out for a 13D. But don't accuse the company of corruption. It seems beneath you and anyone else even bringing that up. Nonsense. Ever hear of Sarbanes Oxley???? Do some research.
A lot of the expenses are paid to clinical trials and third parties. Getting a device through the FDA is terribly expensive. Ever see how much data is delivered to the FDA? Do not assume all the funds are paid to just the ETRM employees. They are still accumulating clinical data as the FDA mandated 5 years of data on existing implant patients. If I had to guess 50% of their expenses went to third parties.
We are spending a lot of time picking apart the people who run this company and they have a huge personal investment in the company. Why don't we just wait and see how the roll out goes and where we are in June.
I still believe there are people accumulating this stock who know a lot more about the roll out.imation The volume is decreasing and in my estimation smart money is buying as much stock as the can shake loose from anxious
owners who get frustrated. I think for instance that the same 100,000 shares is being tossed back and forth between a few players and market makers.